Condition: GERD · Sponsor: Asian Institute of Gastroenterology, India
Primary Objective • To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily. Secondary Objectives * To assess the improvement in reflux symptoms using the GERD-Q score at 8 weeks. * To evaluate the incidence of adverse events across treatment groups.
This description comes directly from the study's public registry record.
Rajesh Goud Mr Maragoni, M.Pharm · 04023378888 · rajeshgoud761@gmail.com
Zaheer Dr Nabi, MD DNB · 04023378888 · zaheernabi1978@gmail.com
Always discuss trial participation with your own doctor first.
| Asian Institute of Gastroenterology /Aig Hospitals | Hyderabad, Telangana, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06953986